Diagnosis and Management of Pituitary Disorders - part 3 docx

... et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 2005 ;33 6:747–7 53. 81. Berndt ... Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem 20 03; 2 53: 65–70. 38 . Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and ... adipokine. Nature 2005; 436 :33 7 33 8.5Detection and Diagnosis of Type 2 DiabetesAdrian VellaCONTENTSIntroductionHyperglycemia and Vascular Risk in PopulationsFPG and 2hPG for Predicting...

... treatment and risk of complications inpatients with type 2 diabetes (UKPDS 33 ). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 ;35 2(9 131 ): 837 – 53. 3. Effect of intensive blood-glucose ... Med 20 03; 348(5) :38 3– 93. 6. The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on thedevelopment and progression of long-term complications ... analysis of 70 patients. Arch Intern Med 1980;140 (3) :37 0 3. 230 . Sola E, Morillas C, Garzon S, Gomez-Balaguer M, Hernandez-Mijares A. Association between diabetic ketoacidosis and thyrotoxi-cosis....

... intervention and cardiovascular disease in patients with type 2 DM. N Engl J Med20 03; 34 8 :38 3 39 3.Chapter 18 / Management of Coronary Artery Disease in Type 2 Diabetes Mellitus 31 71 23. European ... p=0.19CAD 13. 7% PTCA 35 3 (19 .3% ) 5 Yr Mortality 19.4% CABG RR 1.87 [1.24, 2.82] 34 .5% PTCAEAST Multivessel 39 2 8 Yr Mortality 17 .3 % CABG p = 0.40CAD 90 ( 23. 0) 20.7 % PTCA 3 Yr Death, MI, 27 .3% CABG ... trial. Lancet 19 93; 34 1:5 73 580.190. Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass...

... Science UniversityBeaverton, ORISBN: 97 8-1 -5 882 9-7 9 4-5 e-ISBN: 97 8-1 -6 032 7-0 4 3- 4 Library of Congress Control Number: 20089 235 01©2008 Humana Press, a part of Springer Science+Business Media, LLCAll ... for the ß-cell loss through a combination of partial ß-cell regeneration and hyperfunction of theremaining ß-cells, and thus remain normoglycemic under normal circumstances. The partial ß-cell ... 2002;2:216–222. 137 . Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005 ;37 :34 7 35 6. 138 . Nyholm B, Qu Z, Kaal A, et al. Evidence of an increased number of type 11b muscle fibers in insulin-resistant...

... 6.6(<0.00 03) (<0.01)FPG mg/dL 117 120 115 133 117 127 124 119(<0.0001)Hypoglycemia 3. 0 5.1 4.1 9.9 0.7 3. 4 - - events/patient-yr (<0.0 03) (<0.0001) (<0.05)Weight-gain Kg 3. 0 2.8 ... control of muscle glucose uptake. Clin Exp Pharmacol Physiol2005 ;32 :31 9 32 3.44. Coderre L, Kandror KV, Vallega G, Pilch PF. Identification and characterization of an exercise-sensitive pool of glucose ... blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33 ). Lancet, 1998. 35 2(9 131 ): 837 – 53. 52....

... 258 Goff and Cushmanover either monotherapy (79), a trial of the combination of trandolapril and verapamil showed no benefit of addingverapamil to trandolapril or even of verapamil ... lifestyle regimen of 3. 06 on a 4 point262 Goff and Cushman 38 . West KM, Ahuja MM, Bennett PH, et al. Interrelationships of microangiopathy, plasma glucose and other risk factors in 35 83 diabeticpatients: ... events: results of prospectively-designed overviews of randomised trials. Lancet 20 03; 362:1527–1 535 .61. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens...

... bandedgastroplastyGastricbypass–25 30 35 –40–450.0No .of SubjectsControlBandingVertical banded gastroplasty627156451 34 585150 438 34 594154 438 34 5871 53 438 34 577149429 33 5 63 150417 32 542147412 32 535 14440129627156451 34 Gastric ... Treatment -3 0 -2 5 -2 0 -1 5 -1 0 -5 004wk8wk12wk16wk20wk24wk28wk 32 wk 36 wklb.PlaceboQ O Mo. ContinuedMunro JF et al. Br Med J 1968 Feb 10;1(5588) :35 2 -4 Fig. 3. Intermittent ... HS P 339 34 4 ,1970Academic Press New York, London. 3. Hare JW., White P; Gestational Diabetes and the White Classification, Diabetes Care1980 ;3: 394 39 6.4. Jovanovic L, ed in chief. Medical Management...

... Endocrinol Metab 2004;89 :38 35 38 40.92. Ortega-Gonzalez C, Luna S, Hernandez L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazonein obese, insulin-resistant women ... Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycysticovary syndrome. N Engl J Med 1999 ;34 0: 131 4– 132 0.Chapter 23 / Metabolic Complications of PCOS 38 960. Vgontzas AN, ... rare disorders has enhanced our understanding of the regulation of insulin secretion and glucose homeostasis, and may provide clues to a better understanding of the genetic basis of type 1 and...

... diabetesepidemiology of, 39 1 39 3history of, 39 3treatment for, 39 4 39 6E-selectin, 101Estrogen-related receptor  in muscle, 40Euglycemia, 195–196See also HypoglycemiaEurope and prevalence of diabetes, 3 European ... fatty liver disease (NAFLD), 35 1 diagnosis of, 35 5 35 8natural history of, 35 8 35 9related cirrhosis, 35 3therapies for, 35 9Nonalcoholic steatohepatitis (NASH), 158, 35 1Nonsulfonylurea secretagogues ... for, 118–119 and care management, 237 – 238 catecholamines and, 204cerebrovascular disease and, 32 2 32 3 diagnosis of, 32 3 32 5in children and adolescents, 7–8chronic gastrointestinal symptoms with,...